Latest edition: 02 September 2025
Latest edition: 02 September 2025
The majority stake transaction marks one of the largest deals in healthcare this year amid a tepid private equity landscape.
Trump has asked pharma companies to justify efficacy for their Covid-19 drugs as he attempts to quell unrest in his administration.
In the real-world trial, Novo Nordisk's Wegovy showed a significant reduction in cardiovascular events compared to Eli Lilly’s Zepbound.
A Cox proportional hazard analysis revealed that higher leg MWR reduced cardiovascular-cause mortality risk.
The decision by the NMPA was informed by the outcomes of the Phase Ib Beamion-LUNG 1 study.
Charm’s molecule is designed to overcome the safety and long-term efficacy issues impacting first-generation menin inhibitors such as Syndax’s Revuforj.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
